• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cancer Res Treat . Risk of Coronavirus Disease Incidence, Severe Presentation, and Mortality in Patients with Lung Cancer

tetano

Editor, Senior Moderator
Cancer Res Treat


. 2020 Dec 28.
doi: 10.4143/crt.2020.1242. Online ahead of print.
Risk of Coronavirus Disease Incidence, Severe Presentation, and Mortality in Patients with Lung Cancer


Bumhee Yang[SUP] 1 [/SUP], Hayoung Choi[SUP] 2 [/SUP], Sun-Kyung Lee[SUP] 3 4 [/SUP], Sung Jun Chung[SUP] 3 [/SUP], Yoomi Yeo[SUP] 3 [/SUP], Yoon Mi Shin[SUP] 1 [/SUP], Dong Won Park[SUP] 3 [/SUP], Tai Sun Park[SUP] 3 [/SUP], Ji-Yong Moon[SUP] 3 [/SUP], Tae-Hyung Kim[SUP] 3 [/SUP], Yun Su Sim[SUP] 2 [/SUP], Ho Joo Yoon[SUP] 3 [/SUP], Jang Won Sohn[SUP] 3 [/SUP], Hyun Lee[SUP] 3 [/SUP], Sang-Heon Kim[SUP] 3 [/SUP]



Affiliations

Abstract

Purpose: This study aimed to analyze whether patients with lung cancer have a higher incidence of coronavirus disease (COVID-19), severe presentation, and higher mortality than those without lung cancer.
Materials and methods: A nationwide cohort of confirmed COVID-19 (n=8,070) between January 1, 2020, and May 30, 2020, and a 1:15 age-, sex-, and residence-matched cohort (n=121,050) were constructed. A nested case-control study to compare the proportion of patients with lung cancer between the COVID-19 cohort and the matched cohort.
Results: The proportion of patients with lung cancer was significantly higher in the COVID-19 cohort (0.5% [37/8,070]) than in the matched cohort (0.3% [325/121,050]) (p=0.002). The adjusted odds ratio [OR] of having lung cancer was significantly higher in the COVID-19 cohort than in the matched cohort (adjusted OR = 1.51, 95% confidence interval [CI] = 1.05-2.10). Among patients in the COVID-19 cohort, compared to patients without lung cancer, those with lung cancer were more likely to have severe COVID-19 (54.1% vs. 13.2%, p < 0.01), including mortality (18.5% vs. 2.8%, p < 0.01). The adjusted OR for the occurrence of severe COVID-19 in patients with lung cancer relative to those without lung cancer was 2.24 (95% CI = 1.08-4.74).
Conclusion: The risk of COVID-19 incidence and severe presentation, including mortality, may be higher in patients with lung cancer than in those without lung cancer.

Keywords: COVID-19; Lung neoplasms; Mortality.
 
Back
Top Bottom